Clinical Trial Update: Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing a synthetic PvCS-derived vaccine for malaria in naive and semi-immune volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Vivax Malaria

Drugs mentioned

• Synthetic vaccine derived from Plasmodium vivax circumsporozoite protein

Snippet

Sponsor: Malaria Vaccine and Drug Development Center | Conditions: Malaria, Vivax | Phase 2 | Status: UNKNOWN